LON:HEMOHemogenyx Pharmaceuticals Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Hemogenyx Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 7.90 +0.20 (+2.60 %) (As of 07/14/2020) Add Compare Share Today's Range 7.39Now: GBX 7.90▼ 8.1050-Day Range 5.20MA: GBX 6.77▼ 952-Week Range 0.06Now: GBX 7.90▼ 15.25Volume2.77 million shsAverage Volume8.01 million shsMarket Capitalization£34.26 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing CDX bi-specific antibody, an immunotherapy product for patient conditioning undergoing bone marrow/hematopoietic stem cell (BM/HSC) transplants and/or for relapsed acute myelogenous leukemia patients; and Hu-PHEC, a cell therapy product for BM/HSC transplants. The company has a research collaboration agreement with The Rockefeller University to develop treatments for autoimmune diseases. Hemogenyx Pharmaceuticals Plc was founded in 2013 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Hemogenyx Pharmaceuticals. Previous Next 2.0 Community Rank Outperform VotesHemogenyx Pharmaceuticals has received 55 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHemogenyx Pharmaceuticals has received 80 “underperform” votes. (Add your “underperform” vote.)Community SentimentHemogenyx Pharmaceuticals has received 59.26% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Hemogenyx Pharmaceuticals and other stocks. Vote “Outperform” if you believe HEMO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HEMO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHemogenyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthHemogenyx Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hemogenyx Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Hemogenyx Pharmaceuticals is -19.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hemogenyx Pharmaceuticals is -19.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.40 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:HEMO Previous SymbolLON:SILF CUSIPN/A CIKN/A Websilverfalconplc.com PhoneN/ADebt Debt-to-Equity Ratio415.66 Current Ratio3.05 Quick Ratio2.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.11 per share Price / Cash Flow72.50 Book ValueGBX (0.10) per share Price / Book-79.00Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares433,636,000Market Cap£34.26 million Next Earnings DateN/A OptionableNot Optionable GBX 7.90 +0.20 (+2.60 %) (As of 07/14/2020) 30 days | 90 days | 365 days | Advanced Chart Receive HEMO News and Ratings via Email Sign-up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter. Hemogenyx Pharmaceuticals (LON:HEMO) Frequently Asked Questions How has Hemogenyx Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Hemogenyx Pharmaceuticals' stock was trading at GBX 1.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HEMO stock has increased by 401.6% and is now trading at GBX 7.90. View which stocks have been most impacted by Coronavirus. How were Hemogenyx Pharmaceuticals' earnings last quarter? Hemogenyx Pharmaceuticals PLC (LON:HEMO) released its earnings results on Thursday, April, 30th. The company reported ($0.40) EPS for the quarter. View Hemogenyx Pharmaceuticals' earnings history. Has Hemogenyx Pharmaceuticals been receiving favorable news coverage? Media stories about HEMO stock have trended somewhat negative this week, InfoTrie reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hemogenyx Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the near term. View the latest news about Hemogenyx Pharmaceuticals. Who are some of Hemogenyx Pharmaceuticals' key competitors? Some companies that are related to Hemogenyx Pharmaceuticals include Imugene (IMU), MediGene (MDG1), Ampliphi Biosciences (APHB), Lineage Cell Therapeutics (LCTX), Verseon (VSN), Cocrystal Pharma (COCP), BioTime (BTX), Redx Pharma (REDX), Lineage Cell Therapeutics (LCTX), BiomX (PHGE), OncoCyte (OCX), Senesco Technologies (ELOX), Immunoprecise Antibodies (IPA), Orgenesis (ORGS) and Orgenesis (ORGS). View all competitors. What other stocks do shareholders of Hemogenyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hemogenyx Pharmaceuticals investors own include Arcturus Therapeutics (ARCT), Corbus Pharmaceuticals (CRBP), Curaleaf (CURLF), Incyte (INCY), Remark (MARK), Mirati Therapeutics (MRTX), Niu Technologies (NIU), Ovid Therapeutics (OVID), Regenxbio (RGNX) and Sarepta Therapeutics (SRPT). Who are Hemogenyx Pharmaceuticals' key executives? Hemogenyx Pharmaceuticals' management team includes the following people: Dr. Vladislav Sandler Ph.D., Co-Founder, CEO & DirectorMs. Alexis M. Sandler, Co-Founder & Non-Exec. DirectorMr. Lawrence Pemble, Chief Operating OfficerSir Marc Feldmann Ph.D., MB BS, BSc(Med) Hons, PhD, FRCPath, FRCP, F, Exec. Chairman & Chairman of Advisory BoardMr. Andrew Wright, Financial Controller & Company Sec. What is Hemogenyx Pharmaceuticals' stock symbol? Hemogenyx Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HEMO." How do I buy shares of Hemogenyx Pharmaceuticals? Shares of HEMO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Hemogenyx Pharmaceuticals' stock price today? One share of HEMO stock can currently be purchased for approximately GBX 7.90. How big of a company is Hemogenyx Pharmaceuticals? Hemogenyx Pharmaceuticals has a market capitalization of £34.26 million. What is Hemogenyx Pharmaceuticals' official website? The official website for Hemogenyx Pharmaceuticals is silverfalconplc.com. This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
